Business
Novartis Acquires UK Cancer-Drug Start-up Myricx Bio in $1.1 Billion Deal
Swiss pharmaceutical giant Novartis has announced the acquisition of British start-up Myricx Bio for an initial $1.1 billion, a strategic move to bolster its portfolio of antibody-drug conjugates for treating various solid tumours.
about 2 months ago · 1 source
